First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A-Reference-Cited by-同舟云学术

First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A

Published:2017-05-04 Issue:5 Volume:23 Page:689-696
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Hampton K.¹^ORCID,Chowdary P.²^ORCID,Dunkley S.³,Ehrenforth S.⁴,Jacobsen L.⁴,Neff A.⁵,Santagostino E.⁶,Sathar J.⁷,Takedani H.⁸,Takemoto C. M.⁹,Négrier C.¹⁰

Affiliation:

1. Department of Cardiovascular Science; University of Sheffield; Sheffield UK

2. KD Haemophilia Centre and Thrombosis Unit; Royal Free Hospital; London UK

3. Institute of Haematology; Royal Prince Alfred Hospital; Camperdown,Sydney New South Wales Australia

4. Novo Nordisk; Søborg Denmark

5. Vanderbilt University Medical Center; Nashville TN USA

6. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center; IRCCS Ca' Granda Foundation; Maggiore Hospital Policlinico; Milan Italy

7. Department of Haematology; Ampang Hospital; Selangor Malaysia

8. Department of Joint Surgery; Research Hospital; Institute of Medical Science; University of Tokyo; Tokyo Japan

9. Division of Pediatric Hematology; The Johns Hopkins University School of Medicine; Baltimore MD USA

10. Hemostasis and Thrombosis Unit; Louis Pradel Hospital; Université Claude Bernard; Lyon France

Funder

Novo Nordisk

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.13246/fullpdf

Reference14 articles.

1. Turoctocog alfa for the treatment of hemophilia A;Haddley;Drugs Today (Barc),2014

2. Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment;Ingerslev;Semin Hematol,2006

3. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian clinical trials;Santagostino;Haemophilia,2015

4. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy;Mauser-Bunschoten;Haemophilia,2009

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A single‐centre experience of 29 total ankle replacement in haemophiliac patients: Therapeutic management, factor consumption and cost;Haemophilia;2023-12-11

2. Cases of less‐than‐expected FVIII activity in previously treated patients during post‐marketing surveillance of N8‐GP;Haemophilia;2023-09-20

3. Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022;Haemophilia;2022-05

4. Clinical outcomes after joint surgery in patients on turoctocog alfa pegol (N8‐GP) prophylaxis: A post hoc analysis;Haemophilia;2021-11-22

5. Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP);Patient Preference and Adherence;2021-11